Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

N/AActive Not RecruitingNCT05181488

Yona Cho80 enrolled

Overview

This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Resectable Pancreatic Cancer

Interventions

intraoperative radiotherapy, IORTRADIATION

A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically diagnosed with adenocarcinoma of the pancreas or clinically diagnosed with imaging examinations or tumor markers * 20 years or older * Performance status 0-2 based on Eastern Cooperative Oncology Group (ECOG) * Patients with surgically resectable or borderline resectable and advanced pancreatic cancer that can be resected after neoadjuvant chemotherapy * Patients who voluntarily decided to participate in this clinical study and signed a written informed consent Exclusion Criteria: * History of previous abdominal irradiation. * When the treatment area is not included in the appropriate radiation field according to the judgment of the radiation oncologist or Durgeon * Distant metastasis * Other systemic conditions that, under the judgment of the attending physician, would be difficult to undergo surgery or radiiotherapy

Locations (1)

Gangnam Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

3-year local recurrence rate

A local recurrence is defined as reappearance of cancer in the ipsilateral preserved breast or chest wall. The 3-year local recurrence rate is calculated using the Kaplan-Meier method.

Time frame: 3 year after intraoperative radiotherapy

Secondary Outcomes

post-operative complication

Evaluation of safety, including adverse events, was performed by the Principal Investigator and delegated participating investigators in the Department of Surgery and Radiation Oncology outpatient clinic. Toxicity is evaluated within 3 months (acute) and thereafter (chronic) after surgery, and it is performed through a questionnaire and physical examination at every visit up to 1 year after surgery and recorded.

Time frame: 3 year after intraoperative radiotherapy

disease free survival

Disease-free survival is defined as the time from intraoperative radiotherapy to recurrence of tumor, death or last patient contact.

Time frame: 1 year and 2 year after intraoperative radiotherapy.

Overall survival

Overall survival was defined as the time from intraoperative radiotherapy to death or last patient contact.

Time frame: 1 year and 2 year after intraoperative radiotherapy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.